PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

The 420 mg strength of Hercessi, a biosimilar to Herceptin, is used to treat HER2-overexpressing breast and gastric or ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) ...

Accord BioPharma has received FDA approval for IMULDOSA, a biosimilar to STELARA, for treating chronic inflammatory conditions like psoriasis and Crohn's disease. Scheduled for a 2025 launch, it aims ...

The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.

The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...

The 2007 Honda Accord makes a viable option for those in search of a modest family sedan or a well-appointed cruiser. Accord's 2.4L engine produces more horsepower and better fuel economy than the ...

I drove her off the lot new on Jan 2000, two months after the birth of my daughter. Just last year my daughter learned how to drive in the same Honda Accord. I am gonna miss this car.